Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Chen R; Zinzani PL; Fanale MA; Armand P; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP

doi:10.1200/jco.2016.72.1316

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Identifier:nobleid.org/w1/20260526/A28C2AC3

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/A28C2AC3.svg?ark=w1%2F20260526%2FA28C2AC3)](https://nobleid.org/work/w1/20260526/A28C2AC3)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Identifier:nobleid.org/w1/20260526/A28C2AC3

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/A28C2AC3.svg?ark=w1%2F20260526%2FA28C2AC3)](https://nobleid.org/work/w1/20260526/A28C2AC3)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work